Novartis' Afinitor nabs FDA nod to treat kids' brain tumors; Abbott gets new Humira use in EU;

 @FiercePharma: Two drugmakers hit the Forbes "Fab 50" in Asia: Australia's CSL and India's Sun Pharma. Item | Follow @FiercePharma

> Novartis ($NVS) won FDA approval for a new formulation of its Afinitor cancer treatment, Afinitor Disperz, for children with a rare type of brain tumor. Report

> On the heels of an FDA panel recommendation in the U.S., Abbott Laboratories' ($ABT) Humira nabbed a new use in Europe in patients with moderately active Crohn's disease. Report

> GlaxoSmithKline ($GSK) said it would continue to negotiate with local officials in Montrose, Scotland, after officials rejected its wind-turbine plan designed to power a local plant that's slated for expansion. Report

> Brazil's Hypermarcas is reaping the rewards of a restructuring that refocused its operations on drugs and beauty products. Report

> Quality Packaging Specialists, a New Jersey pharma packaging firm, will move a plant to Pennsylvania and create 283 jobs there over the next three years, officials said. Report

> Switzerland's Siegfried said its active pharmaceuticals ingredient business grew by 2.9% for the first 6 months of 2012, to $185 million, as it prepares to expand operations in China. Report

> China's Fosun Pharma nabbed $47 million in financing from the World Bank's International Finance Corporation, to upgrade manufacturing facilities, including those in less-developed regions. Report

Medical Device News

 @FierceMedDev: Bacterin International, a maker of bone graft material and antimicrobial coatings, won $25M in financing from OrbiMed. Release | Follow @FierceMedDev

 @MarkHFierce: BSX is slashing more jobs and splitting its cardio business in two--undoing changes enacted by the old CEO. More | Follow @MarkHFierce

 @DamianFierce: Baxter is recalling four Automix devices over a deadly malfunction risk. The FDA has labeled it a Class I. News | Follow @DamianFierce

> Zynex gets 510(k) for urinary incontinence device. News

> MDxHealth's revenues soar, losses deepen in H1. Item

Biotech News

 @FierceBiotech: XBiotech hatches big plans for Austin campus. Item | Follow @FierceBiotech

 @JohnCFierce: At long last, Ironwood gets its OK, shifts to commercialization alongside development. News | Follow @JohnCFierce

 @RyanMFierce: After reading through this OvaScience S-1, looks like VCs are in fact cashing out, some want to unload most of their shares. | Follow @RyanMFierce

> Cincy biotech spinoff snags $27M A round for vascular drug work. Story

> Novartis ready to present blockbuster COPD hopeful QVA149 to regulators. Article

> Teva's Neupogen-knockoff approval highlights slow progress of biosims. More

> J&J grabs Genmab's promising leukemia antibody in $1.1B deal. News

Pharma Manufacturing News

 @EricPFierce: Hospira goes back to Orchid, picks up API plant, R&D center for $200 million. Good news tainted a bit by FDA warning. Story | Follow @EricPFierce

> Closed plants lead Novartis to plead for vet loyalty. Story

> Claris squares off against former partners in U.S. injectables market. Article

> Scots reject GSK wind turbines; tidal turbines up next. Story

Vaccines News

 @AlisonBFierce: What does AstraZeneca's new CEO mean to vaccinemaker MedImmune? More | Follow @AlisonBFierce

> S. Korea, Sweden partner up to find Alzheimer's vaccine. Item

> West Nile virus breaks out in the South. News

> CSL nets closeout letter after FDA violations. More

> Flu adjuvant adds promise to vaccine. Report

And Finally ... Tuberculosis cases around the world are growing increasingly resistant to virtually all treatments, a study found. Report

Suggested Articles

Dupixent has been posting strong sales growth for Sanofi, and now the drugmaker has a third FDA indication to keep the momentum going.

Novartis has found itself caught up in a controversy about ingredients shipped to Syria that critics say could have been used to make sarin gas. 

AbbVie made a major splash Tuesday with its proposed $63 billion buyout of Allergan. But analysts and investors were hardly impressed.